LLY

1,017.19

-2.72%↓

JNJ

244.07

+0.3%↑

ABBV

227.12

-2.44%↓

NVS

165.06

-0.79%↓

MRK

120.66

-0.62%↓

LLY

1,017.19

-2.72%↓

JNJ

244.07

+0.3%↑

ABBV

227.12

-2.44%↓

NVS

165.06

-0.79%↓

MRK

120.66

-0.62%↓

LLY

1,017.19

-2.72%↓

JNJ

244.07

+0.3%↑

ABBV

227.12

-2.44%↓

NVS

165.06

-0.79%↓

MRK

120.66

-0.62%↓

LLY

1,017.19

-2.72%↓

JNJ

244.07

+0.3%↑

ABBV

227.12

-2.44%↓

NVS

165.06

-0.79%↓

MRK

120.66

-0.62%↓

LLY

1,017.19

-2.72%↓

JNJ

244.07

+0.3%↑

ABBV

227.12

-2.44%↓

NVS

165.06

-0.79%↓

MRK

120.66

-0.62%↓

Search

Charles River Laboratories International Inc

Abrir

SetorSaúde

151.09 -4.68

Visão Geral

Variação de preço das ações

24h

Atual

Mín

145.06

Máximo

162.26

Indicadores-chave

By Trading Economics

Rendimento

2.9M

56M

Vendas

-27M

1B

EPS

2.43

Margem de lucro

5.529

Funcionários

18,700

EBITDA

-23M

198M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+45.8% upside

Dividendos

By Dow Jones

Próximos Ganhos

18 de fev. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-862M

7.9B

Abertura anterior

155.77

Fecho anterior

151.09

Sentimento de Notícias

By Acuity

100%

0%

341 / 351 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bullish Evidence

Charles River Laboratories International Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

17 de fev. de 2026, 23:44 UTC

Ações em Alta

Stocks to Watch: La-Z-Boy, Palo Alto Networks, Caesars

17 de fev. de 2026, 23:20 UTC

Ganhos

Palo Alto Networks Lifts FY26 Revenue Outlook as 2Q Profit Jumps -- Update

17 de fev. de 2026, 22:57 UTC

Ganhos

Santos Fiscal Year Net Profit Falls 33%, Nears Start of Alaska Project

17 de fev. de 2026, 21:59 UTC

Ganhos

Palo Alto Networks Lifts FY26 Revenue Outlook as 2Q Profit Jumps

17 de fev. de 2026, 23:54 UTC

Conversa de Mercado

Nikkei May Rise as Fears About AI Disruption Ease -- Market Talk

17 de fev. de 2026, 23:54 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

17 de fev. de 2026, 23:54 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

17 de fev. de 2026, 23:45 UTC

Conversa de Mercado

Suncorp's Outperformance of IAG Could Be Hard to Sustain -- Market Talk

17 de fev. de 2026, 23:19 UTC

Ganhos

Palo Alto's Guidance Overshadows Strong Earnings. Its Stock Is Down. -- Barrons.com

17 de fev. de 2026, 23:15 UTC

Ganhos

Palo Alto's Guidance Overshadows Strong Earnings. Its Stock Is Down. -- Barrons.com

17 de fev. de 2026, 22:58 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Netflix Would Operate Warner's Studios, HBO Largely the Same -- Market Talk

17 de fev. de 2026, 22:58 UTC

Aquisições, Fusões, Aquisições de Empresas

BlueScope Steel: Board Committed to Optimizing Value For Shareholders

17 de fev. de 2026, 22:57 UTC

Aquisições, Fusões, Aquisições de Empresas

BlueScope Steel to Consider Revised SGH, Steel Dynamics Takeover Bid

17 de fev. de 2026, 22:50 UTC

Aquisições, Fusões, Aquisições de Empresas

Agnico-Eagle Mines Acquired 662,780 Common Shrs of Maple Gold Mines at C$2.45 Per Common Shr >AEM.T

17 de fev. de 2026, 22:44 UTC

Ganhos

Palo Alto Reports Strong Earnings. Its Stock Is Down. -- Barrons.com

17 de fev. de 2026, 22:42 UTC

Ganhos

Santos FY Net Profit Falls 33%, Nears Start of Alaska Project

17 de fev. de 2026, 22:36 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Netflix Sarandos: Paramount Causing Confusion Around Warner Deal -- Market Talk

17 de fev. de 2026, 22:36 UTC

Ganhos

Santos Final Dividend 10.3 U.S. Cents/Security

17 de fev. de 2026, 22:36 UTC

Ganhos

Santos FY Underlying Profit US$898 Million, Down 25%

17 de fev. de 2026, 22:35 UTC

Ganhos

Santos FY Revenue US$4.94 Billion, Down 8%

17 de fev. de 2026, 22:35 UTC

Ganhos

Correct: Santos FY Net Profit US$818 Million, Down 33%

17 de fev. de 2026, 22:35 UTC

Aquisições, Fusões, Aquisições de Empresas

Berkshire Buys New York Times Stock; Sells Apple, Bank of America, Amazon In 4Q -- Barrons.com

17 de fev. de 2026, 22:34 UTC

Ganhos

Santos FY Net Profit US$818 Billion, Down 33%

17 de fev. de 2026, 22:02 UTC

Aquisições, Fusões, Aquisições de Empresas

Berkshire Pares Stakes in Apple and BofA, Adds New York Times Position -- Update

17 de fev. de 2026, 21:50 UTC

Aquisições, Fusões, Aquisições de Empresas

Steel Dynamics: SGH Would Buy BlueScope, On-sell North American Operations to SDI, As Earlier Proposed

17 de fev. de 2026, 21:50 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Tech, Media & Telecom Roundup: Market Talk

17 de fev. de 2026, 21:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

17 de fev. de 2026, 21:49 UTC

Aquisições, Fusões, Aquisições de Empresas

Steel Dynamics Says Revised Proposal Continues to Present Highly Strategic Opportunity For SDI Shareholders

17 de fev. de 2026, 21:48 UTC

Aquisições, Fusões, Aquisições de Empresas

Steel Dynamics: BlueScope Offer a 56% Premium to 52-Week Volume Weighted Average Price

17 de fev. de 2026, 21:48 UTC

Aquisições, Fusões, Aquisições de Empresas

Steel Dynamics: Consideration To Be Comprised Entirely of Cash

Comparação entre Pares

Variação de preço

Charles River Laboratories International Inc Previsão

Preço-alvo

By TipRanks

45.8% parte superior

Previsão para 12 meses

Média 235.25 USD  45.8%

Máximo 265 USD

Mínimo 190 USD

Com base em 10 analistas de Wall Street que oferecem metas de preço de 12 meses para Charles River Laboratories International Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

10 ratings

8

Comprar

2

Manter

0

Vender

Pontuação Técnica

By Trading Central

117.16 / 144.77Suporte e Resistência

Curto Prazo

Strong Bullish Evidence

Médio Prazo

Weak Bullish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

341 / 351 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Baixa

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat